New drug cocktail shows promise for tough pancreatic cancer
NCT ID NCT00885066
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This early-phase study tested a combination of three drugs (gemcitabine, capecitabine, and erlotinib) in 30 people with advanced pancreatic cancer that had already been treated. The main goal was to find the safest dose and understand side effects. This is not a cure, but aims to help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
Conditions
Explore the condition pages connected to this study.